NCI at ASCO 2018
Saturday, June 2
Today is the second day of the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting and we hope you join us in attending NCI Director Dr. Sharpless’ remarks this morning.
You can also visit our experts at one of the NCI-featured sessions listed below, or stop by the NCI Exhibit Booth (#5041) for a “Meet the Experts” session, free publications, and more!
For more information about NCI activities at ASCO, visit the NCI at ASCO 2018 webpage.
At 10:25 AM, join NCI Director Norman E. Sharpless, M.D. at the ASCO Opening Plenary Session for the NCI Director’s Remarks.
To find out more about what Dr. Sharpless is up to at ASCO, follow @NCIDirector on Twitter.
Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial
Komal L. Jhaveri, M.D., FACP - New York University Cancer Institute
8:00 AM - 8:12 AM
Ian E. Krop, M.D., Ph.D. - Dana-Farber Cancer Institute
8:12 AM - 8:24 AM
Get up-to-speed with the latest results from the NCI-MATCH trial at the “Tumor Genomics: Finding the Target, Hitting the Target” session. From 8:00 AM – 8:24 AM, two NCI grantees will discuss “Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophogeal junction (GEJ) adenocarcinomas,” and “Taselisib for PIK3CA-mutated tumors.”
For more information on MATCH, visit the NCI-MATCH Trial webpage
Andrea Apolo, M.D.9:36 AM - 9:48 AM
Listen to NCI’s Dr. Apolo discuss three of the abstracts presented during the "Genitourinary (Nonprostate) Cancer" session: 4503, 4504, 4505.
Norman E Sharpless, M.D.
10:25 AM - 10:50 AM
Join NCI Director Dr. Sharpless for his remarks during the ASCO Opening Plenary Session.
Raffit Hassan, M.D.
1:35 PM - 1:55 PM
At the “Malignant Mesothelioma: Therapies to Get Really Excited About” session, Dr. Hassan will present on immunotherapy and other exciting treatments for malignant mesothelioma.
SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
Andrea Gross, M.D., B.S.
4:00 PM - 4:12 PM
Plexiform neurofibromas (PN) in children with neurofibromatosis type 1 (NF1) can cause substantial morbidity, and there are no approved medical therapies. Join Dr. Gross as she presents her abstract on a phase II study that examined the partial response rate of PN treated with selumetinib and changes in PN related morbidities.
Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells
Sanja Stevanovic, Ph.D.
4:12 PM - 4:24 PM
Adoptive T-cell therapy (ACT) is a promising cancer treatment modality. However, its study in epithelial cancers has been limited. At this session, NCI’s Dr. Stevanovic will present her abstract on a clinical trial of ACT for the treatment of metastatic HPV-associated cancers.